InspireMD Sees Growth in Q2 2025 with Strong Financial Results

InspireMD’s Financial Growth in Q2 2025

MIAMI, InspireMD, Inc. (Nasdaq: NSPR), a leading developer of advanced medical devices, reported significant financial and operational results for the second quarter of 2025. Their CGuard Prime carotid stent system, designed for stroke prevention, continues to gain traction in the market.

Recent Business Highlights

This quarter has been a landmark period for InspireMD. The company achieved several major milestones:

• Achieved premarket application (PMA) approval from the U.S. FDA for the CGuard Prime carotid stent system.
• Launched the CGuard Prime carotid stent system commercially in the U.S. market.
• Secured $58 million in gross proceeds from an equity private placement and warrants exercise, fueling expansion strategies.
• Received CE Mark approval under the European Medical Device Regulation (MDR) for the CGuard Prime, preparing for a launch in the upcoming quarter.
• Strengthened the leadership team with the appointment of Mike Lawless as Chief Financial Officer.
• Appointed Raymond W. Cohen to the Board of Directors.

CEO Marvin Slosman’s Insights

CEO Marvin Slosman expressed enthusiasm about the company’s recent accomplishments, stating, “The past few months have been transformative for InspireMD. We have executed crucial milestones, validating our vision for the CGuard Prime carotid stent system. We are ready to harness our fully trained commercial team’s capabilities to reach our potential.”

He further emphasized, “The $58 million raised reflects strong investor confidence in our future. We are focused on establishing our technology as the standard in treating carotid artery disease and preventing strokes.”

Financial Performance Overview

In Q2 2025, InspireMD reported:

• A total revenue increase of $39,000 (2.3%), reaching $1,778,000 compared to $1,739,000 in Q2 2024.
• The gross profit for the quarter decreased by $18,000 (5.4%) to $313,000, down from $331,000 in Q2 2024.
• Total operating expenses increased to $13,332,000, a rise of 55.2%, reflecting expenses tied to U.S. sales force expansion, launch preparations, and facility costs.
• Net financial expense for the quarter was $132,000, shifting from financial income of $351,000 in Q2 2024 due to foreign exchange impacts.
• The net loss for the quarter was $13,151,000 or $0.26 per share, compared to a loss of $7,909,000 or $0.22 per share in 2024.
• Cash and cash equivalents along with marketable securities stood at $19,374,000 as of June 30, 2025, down from $34,637,000 by the end of 2024.

Looking Ahead

For the six months ended June 30, 2025, InspireMD reported a revenue uptick of $57,000 (1.8%) to $3,307,000 from $3,250,000 in 2024. The company anticipates growth opportunities through continued adoption of the CGuard technology, even amidst market challenges.

Conference Call and Webcast Details

To discuss the financial results and provide updates, InspireMD will host an investor conference call. Here are the details:

Date: Upcoming Tuesday call at 8:30 a.m. ET.

Domestic Call: 1-800-579-2543

International Call: 1-785-424-1789

Conference ID: IMD2Q25

Webcast: [Join Here](https://www.globenewswire.com/Tracker?data=Ryp6-R4QT5RXfsGrOaqlUrFurCO1uUBsvR5mNKOn6mILcr2D9ycA1uQVEGRksqSe_yZTLBe7xhzNo1EJnRFwPinxGVo6g28QOg1z9MbaNdc3BMXH2m6dj66kIec_FXvLw46QK3L7o8vLP-ym_4x7sNOX865_SUcp1dns7QpGJ4QREuudM48lMPhpJ9-nkInh8EWWprixrKJGndOos-ELUV8m_y5mtUp5JkL8N0rbrIjDHS2G5WKi7t4TK9TrF-azFFGbowuNz2z-Na0pJw_ZPaB2IThf43lDqqK17mJUc5z_0Xep6WBlaHNIBECucPer6p0h69wV9p4Z7b23iqyBcxP_Lm9wtK09V0GC7hlLOsZMScP_oFMqibTVihQZ-TF6yy1OIFzg7Iii7VxZuLioAwH2ZOoQyDpPyA6JcUvnjx1rlUsXn9pqnf2aghmbPOqhyWVr2TJgHUOi3KnEPW-L-Q== rel="nofollow" target="_blank")

About InspireMD, Inc.

InspireMD is dedicated to providing superior products utilizing its proprietary MicroNet™ mesh technology. This commitment aims to establish InspireMD products as the industry standard for carotid stenting, boasting remarkable acute results and sustaining long-term stroke-free outcomes. The company's shares are traded on Nasdaq under the ticker symbol NSPR.

Frequently Asked Questions

What major achievements did InspireMD report for Q2 2025?

InspireMD secured FDA approval for the CGuard Prime system, launched it commercially, and raised $58 million to support growth initiatives.

How did InspireMD's revenue change in Q2 2025?

Total revenue increased by $39,000, or 2.3%, reaching $1,778,000 compared to the previous year.

What can investors expect from the upcoming conference call?

The call will discuss financial results and corporate updates, with an interactive Q&A session following the presentation.

What is the focus of InspireMD's future growth?

InspireMD aims to position its CGuard technology as the new standard in carotid artery disease treatment, capitalizing on recent investment support.

Where can investors find more information about InspireMD?

Investors can visit InspireMD's official website or check their filings with the SEC for detailed information.

About The Author

My name is Dylan Bailey, and I am 28 years old. I am an author and an expert on the stock market who specializes in publicly traded companies. Early fascination with the stock market inspired me to seek a finance degree and then delve deeply into the world of stocks. I have developed over the years my abilities to spot investment prospects, assess business performance, and analyze market trends.

My books and articles try to help regular investors understand the nuances of the stock market. Anyone can, in my opinion, make wise investment choices and succeed financially if they have the correct information and resources. In my writing, I combine in-depth research with practical insights and advice that can be put into action. This is done with the intention of assisting readers in navigating the constantly shifting landscape of publicly traded companies.

In addition to writing, I also host webinars and workshops, where I give presentations and share my knowledge with a wider audience. I also write for top financial journals and show up as a guest analyst on financial news shows. I like to travel, spend time with my family, and keep active by playing different sports when I'm not buried in market research.

My goal is to enable people to choose wisely and consciously in their investments, so taking charge of their financial futures. By my work, I hope to create a community of informed and self-assured investors prepared to take advantage of the chances presented by the stock market.

Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.